Treatment of Clinically Organ Confined Prostate Cancer

REFERENCES

• Stephenson RA. Prostate cancer trends in the PSA era: data from the SEER program. AUA News 1997; Sept Oct: 15–22.
   Google Scholar
• Wingo PA, Landis S, Ries L. An adjustment to the 1997 estimate for new prostate cancer cases. Cancer 1997; 80: 1810.
   PubMedGoogle Scholar
• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. Cancer J Clin 1998; 48: 6.
   PubMed Web of Science ®Google Scholar
• Hoeksema MJ, Law C. Cancer mortality rates fall: a turning point for the nation. J Natl Cancer Inst 1996; 88: 1706.
   PubMed Web of Science ®Google Scholar
• Douglas TH, Sesterhenn IA, Mostofi FK, et al. Prostate-specific antigen detected prostate cancer (Stage Tic): an analysis of whole-mount prostatectomy specimens. The Prostate 1997; 32: 59.
   PubMed Web of Science ®Google Scholar
• Moul JW. Treatment options for prostate cancer. Am J Managed Care 1998; 4: 1171.
   Google Scholar
• Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110.
   PubMed Web of Science ®Google Scholar
• Kaftan MW, Eastham JA, Stapleton AMF, et al. A pre-operative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Nat Cancer Inst 1998; 90: 766.
   PubMedGoogle Scholar
• Smith RB, Ehrlich RM. Complications of urologic surgery: prevention and management. 2nd edn. Phila-delphia: WB Saunders Co., 1990.
   Google Scholar
• Walsh PC. Radical retropubic prostatectomy. In: Walsh PC, Retik AB, Stamey TA, Vaughn ED Jr, eds. Campbell's urology, 6th edn. Philadelphia: WB Saun-ders Co., 1992: 2685–96.
   Google Scholar
• Catalona WJ, Basler JW. Return of erections and urinary continence following nerve-sparing radical retropubic prostatectomy. J Urol 1993; 150: 905.
   PubMed Web of Science ®Google Scholar
• Fowler FJ, Barry MJ, Lu-Yao G. Patient-reported complications and follow-up treatment after radical prostatectomy-the national medical experience: 1988-1990 (updated 1993). Urology 1993; 42: 622–9.
   Google Scholar
• Talcot JA. Patient-reported impotence and incontinence after nerve sparing radical prostatectomy. J Natl Cancer Inst 1997; 89: 1117.
   PubMedGoogle Scholar
• Goldenberg SL, Klotz LH, Srigley J, et al. Randomized prospective, controlled study comparing radical prosta-tectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 1996; 156: 873.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by andro-gen blockade in clinical stage B2 (T2bNxM0). J Urol 1995; 154: 424.
   PubMed Web of Science ®Google Scholar
• Van Poppel H, De Ridder D, Elgamal AA, et al. Neoadjuvant hormonal therapy before radical prosta-tectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J Urol 1995; 154: 429.
   PubMed Web of Science ®Google Scholar
• Dalkin BL, Ahmann FR, Nagle R, Johnson CS. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol 1996; 155: 1357.
   PubMed Web of Science ®Google Scholar
• Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3NoMo prostatic carcinoma. Urology 1997; Suppl 49: 65.
   Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994; 44: 29.
   Web of Science ®Google Scholar
• Huggosson J, Abrahamsson PA, Ahlgren G, et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 1994; 29: 413.
   Web of Science ®Google Scholar
• Bonney WW, Schned AR, Timberlake DS. Neoadjuvant androgen ablation for localized prostate cancer. J Urol 1998; 160: 1754.
   Google Scholar
• Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Physics 1995; 32: 287.
   PubMed Web of Science ®Google Scholar
• Leibel SA, Zelefsky MJ, Kutcher GJ. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase I dose-escalation study. J Urol 1994; 152: 1792.
   Google Scholar
• Roach M, Picket B, Rosenthal S, et al. Defining treatment margins foe 3-D based six field conformal (SFC) irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28: 267.
   PubMed Web of Science ®Google Scholar
• Roach M, Pickett B, F-Akazawa P. Weil M. Imple-mentation of newer radiotherapeutic technology in the management of prostate cancer. In: Mittal B, Purdy J, Ang K, eds. Advances in radiation therapy, 1st edn. Norwell, MA, USA: Kuwer Academic Publishers; (Rosen ST, ed. Cancer Treatment Research; vol. 1) 1998: 247.
   Google Scholar
• Roach M. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Semin Urol Oncol 1996; 14: 32.
   PubMedGoogle Scholar
• Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Ther-apy Oncology Group protocol 85-31. J Clin Oncol 1997; 15: 1013.
   PubMed Web of Science ®Google Scholar
• Botta M, Gonzalez D, Warde P. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295.
   Google Scholar
• Holm I-1H, Juul N, Pedersen JF, et al. Transperineal 125-iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1993; 130: 283.
   Google Scholar
• Blasko JC, Grimm PD, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993; 3: 240.
   Google Scholar
• Grimm PD, Blasko J, Ragde H, et al. Transperineal ultrasound guided 1125/Pd103 brachytherapy for early stage prostate cancer: update on clinical experience at 7 years. Int J Radiat Oncol Biol Phys 1997; 39: 219.
   Web of Science ®Google Scholar